Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
28
PDSB Quote, Financials, Valuation and Earnings
Last price:
$0.70
Seasonality move
:
-8.46%
Day range:
$0.68 - $0.74
52-week range:
$0.68 - $2.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.14x
Volume:
449.9K
Avg. volume:
800.4K
1-year change:
-53.87%
Market cap:
$39.1M
Revenue:
--
EPS (TTM):
-$0.82
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
-- | -$0.20 | -- | -4.94% | $7.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
CLRB
Cellectar Biosciences, Inc.
|
-- | -$1.22 | -- | -20.45% | $47.00 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
PAVM
PAVmed, Inc.
|
-- | -$4.50 | -100% | -78.99% | $9.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
$0.72 | $7.50 | $39.1M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
CLRB
Cellectar Biosciences, Inc.
|
$3.04 | $47.00 | $5.5M | -- | $0.00 | 0% | 137.94x |
|
IMNN
Imunon, Inc.
|
$3.27 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
PAVM
PAVmed, Inc.
|
$10.80 | $9.50 | $10M | 0.30x | $0.00 | 0% | 5,045.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
65.52% | 0.267 | 37.29% | 1.97x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
CLRB
Cellectar Biosciences, Inc.
|
4.4% | -0.908 | 3.58% | 2.56x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
PAVM
PAVmed, Inc.
|
20.6% | -0.669 | 34.03% | 0.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
-$15.1K | -$8.1M | -91.45% | -196.47% | -- | -$5.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
CLRB
Cellectar Biosciences, Inc.
|
-$52.3K | -$4.9M | -154.34% | -160.56% | -- | -$4.3M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
PAVM
PAVmed, Inc.
|
-$72K | -$4.8M | 4.06% | 8.75% | -96880% | -$899K |
PDS Biotechnology Corp. vs. Competitors
-
Which has Higher Returns PDSB or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of 25.76%. PDS Biotechnology Corp.'s return on equity of -196.47% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About PDSB or ACAD?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 948.95%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that PDS Biotechnology Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe PDS Biotechnology Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is PDSB or ACAD More Risky?
PDS Biotechnology Corp. has a beta of 1.210, which suggesting that the stock is 21.023% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock PDSB or ACAD?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or ACAD?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. PDS Biotechnology Corp.'s net income of -$9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns PDSB or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of 20.1%. PDS Biotechnology Corp.'s return on equity of -196.47% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About PDSB or ALNY?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 948.95%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that PDS Biotechnology Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe PDS Biotechnology Corp. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is PDSB or ALNY More Risky?
PDS Biotechnology Corp. has a beta of 1.210, which suggesting that the stock is 21.023% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock PDSB or ALNY?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or ALNY?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. PDS Biotechnology Corp.'s net income of -$9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns PDSB or CLRB?
Cellectar Biosciences, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of --. PDS Biotechnology Corp.'s return on equity of -196.47% beat Cellectar Biosciences, Inc.'s return on equity of -160.56%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M -
What do Analysts Say About PDSB or CLRB?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 948.95%. On the other hand Cellectar Biosciences, Inc. has an analysts' consensus of $47.00 which suggests that it could grow by 1446.05%. Given that Cellectar Biosciences, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe Cellectar Biosciences, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 CLRBCellectar Biosciences, Inc.2 2 0 -
Is PDSB or CLRB More Risky?
PDS Biotechnology Corp. has a beta of 1.210, which suggesting that the stock is 21.023% more volatile than S&P 500. In comparison Cellectar Biosciences, Inc. has a beta of 0.323, suggesting its less volatile than the S&P 500 by 67.747%.
-
Which is a Better Dividend Stock PDSB or CLRB?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. Cellectar Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or CLRB?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than Cellectar Biosciences, Inc. quarterly revenues of --. PDS Biotechnology Corp.'s net income of -$9M is lower than Cellectar Biosciences, Inc.'s net income of -$4.4M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while Cellectar Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 137.94x for Cellectar Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M
-
Which has Higher Returns PDSB or IMNN?
Imunon, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of --. PDS Biotechnology Corp.'s return on equity of -196.47% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About PDSB or IMNN?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 948.95%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 644.14%. Given that PDS Biotechnology Corp. has higher upside potential than Imunon, Inc., analysts believe PDS Biotechnology Corp. is more attractive than Imunon, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 IMNNImunon, Inc.3 1 0 -
Is PDSB or IMNN More Risky?
PDS Biotechnology Corp. has a beta of 1.210, which suggesting that the stock is 21.023% more volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock PDSB or IMNN?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or IMNN?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. PDS Biotechnology Corp.'s net income of -$9M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns PDSB or PAVM?
PAVmed, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of -120220%. PDS Biotechnology Corp.'s return on equity of -196.47% beat PAVmed, Inc.'s return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M PAVMPAVmed, Inc.-1440% -$0.29 $35.1M -
What do Analysts Say About PDSB or PAVM?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 948.95%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 2538.89%. Given that PAVmed, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe PAVmed, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 PAVMPAVmed, Inc.1 0 0 -
Is PDSB or PAVM More Risky?
PDS Biotechnology Corp. has a beta of 1.210, which suggesting that the stock is 21.023% more volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.118, suggesting its more volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock PDSB or PAVM?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or PAVM?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. PDS Biotechnology Corp.'s net income of -$9M is lower than PAVmed, Inc.'s net income of -$6M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 5,045.37x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M PAVMPAVmed, Inc.5,045.37x 0.30x $5K -$6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 9
Bill Holdings, Inc. [BILL] is up 3.7% over the past day.
Buy
75
PRLB alert for Feb 9
Proto Labs, Inc. [PRLB] is down 2.16% over the past day.
Sell
30
MSTR alert for Feb 9
Strategy, Inc. [MSTR] is up 2.59% over the past day.
